应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02268 药明合联
未开盘 08-18 16:08:05
69.850
+4.900
+7.54%
最高
70.600
最低
65.000
成交量
998.57万
今开
65.000
昨收
64.950
日振幅
8.62%
总市值
884.30亿
流通市值
884.30亿
总股本
12.66亿
成交额
6.84亿
换手率
0.79%
流通股本
12.66亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
港股异动 | 药明合联(02268)午后涨超8% 新加坡基地BCM3双功能产线成功完成GMP放行
智通财经 · 08-18 13:36
港股异动 | 药明合联(02268)午后涨超8% 新加坡基地BCM3双功能产线成功完成GMP放行
医药概念股走强 金斯瑞生物科技（01548）上涨7.67% 机构指板块中长期布局良机已至
金吾财讯 · 08-18 10:15
医药概念股走强 金斯瑞生物科技（01548）上涨7.67% 机构指板块中长期布局良机已至
港股创新药概念股盘初活跃，金斯瑞生物科技、海西新药涨超8%
老虎资讯综合 · 08-18 09:35
港股创新药概念股盘初活跃，金斯瑞生物科技、海西新药涨超8%
异动解读｜药明合联盘中上涨3.08%，中报临近叠加板块联动延续走强
行情直击 · 08-18 09:35
异动解读｜药明合联盘中上涨3.08%，中报临近叠加板块联动延续走强
港股创新药概念股盘中走强，和黄医药涨超7%，药明生物、金斯瑞生物科技涨超5%
老虎资讯综合 · 08-17 10:08
港股创新药概念股盘中走强，和黄医药涨超7%，药明生物、金斯瑞生物科技涨超5%
异动解读｜药明合联盘中上涨4.11%，中报临近叠加板块联动走强
行情直击 · 08-17 10:05
异动解读｜药明合联盘中上涨4.11%，中报临近叠加板块联动走强
异动解读｜药明合联盘中下跌3.08%，报61.4港元
行情直击 · 08-14
异动解读｜药明合联盘中下跌3.08%，报61.4港元
【券商聚焦】中信建投：AI制药大有可为，产业链有望持续受益
金吾财讯 · 08-14
【券商聚焦】中信建投：AI制药大有可为，产业链有望持续受益
创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升
金吾财讯 · 08-11
创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升
异动解读｜药明合联盘中上涨3.6%，机构增持突破举牌线叠加中报预期升温
行情直击 · 08-11
异动解读｜药明合联盘中上涨3.6%，机构增持突破举牌线叠加中报预期升温
药明合联：Schroders PLC增持，好仓比例升至5.01%
港股披露 · 08-10
药明合联：Schroders PLC增持，好仓比例升至5.01%
异动解读｜药明合联盘中上涨3.39%，中报业绩预期升温叠加CXO板块联动走强
行情直击 · 08-10
异动解读｜药明合联盘中上涨3.39%，中报业绩预期升温叠加CXO板块联动走强
港股异动 | 创新药概念多数走高 创新药企陆续迎业绩窗口 后续学术会议有望带来密集催化
智通财经 · 08-07
港股异动 | 创新药概念多数走高 创新药企陆续迎业绩窗口 后续学术会议有望带来密集催化
医药股强势走强 再鼎医药（09688）涨13.97%、药明生物（02269）涨5.41%
金吾财讯 · 08-07
医药股强势走强 再鼎医药（09688）涨13.97%、药明生物（02269）涨5.41%
异动解读｜药明合联盘中上涨3.07%，中报业绩预期升温叠加CXO板块持续走强
行情直击 · 08-07
异动解读｜药明合联盘中上涨3.07%，中报业绩预期升温叠加CXO板块持续走强
异动解读｜药明合联盘中上涨4.34%，中报业绩预期升温叠加多家大行看好
行情直击 · 08-06
异动解读｜药明合联盘中上涨4.34%，中报业绩预期升温叠加多家大行看好
药明合联7月股份变动月报表，已发行股份增至1,266,466,942股
公告速递 · 08-05
药明合联7月股份变动月报表，已发行股份增至1,266,466,942股
异动解读｜药明合联盘中上涨5.66%，CXO板块集体走强叠加中报业绩预期升温
行情直击 · 08-04
异动解读｜药明合联盘中上涨5.66%，CXO板块集体走强叠加中报业绩预期升温
异动解读｜药明合联盘中下跌3.21%，野村下调目标价并削减盈利预测
行情直击 · 07-30
异动解读｜药明合联盘中下跌3.21%，野村下调目标价并削减盈利预测
异动解读｜药明合联盘中下跌3.04%，报52.7港元
行情直击 · 07-28
异动解读｜药明合联盘中下跌3.04%，报52.7港元
加载更多
公司概况
公司名称：
药明合联
所属市场：
SEHK
上市日期：
--
主营业务：
药明合联生物技术有限公司是一家主要从事提供提供抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司。该公司的服务包括生物偶联药物、单克隆抗体中间体及生物偶联药物相关连接子及有效载荷的发现、工艺开发及优良生产质量管理规范（GMP）生产。该公司透过按有偿服务（FFS）基准的合约和按全时当量（FTE）基准的合约向客户提供CRDMO服务。该公司主要在国内市场、北美、欧洲和世界其他地区市场开展业务。
发行价格：
--
{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":69.85,"timestamp":1787040485007,"preClose":64.95,"halted":0,"volume":9985743,"delay":0,"changeRate":0.07544264819091595,"floatShares":1266000000,"shares":1266000000,"eps":1.3021176582840468,"marketStatus":"未开盘","change":4.9,"latestTime":"08-18 16:08:05","open":65,"high":70.6,"low":65,"amount":684277706,"amplitude":0.08622,"askPrice":70,"askSize":66000,"bidPrice":69.85,"bidSize":11000,"shortable":3,"etf":0,"ttmEps":1.3021176582840468,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787103000000},"marketStatusCode":0,"adr":0,"listingDate":1700150400000,"exchange":"SEHK","adjPreClose":64.95,"openAndCloseTimeList":[[1787016600000,1787025600000],[1787029200000,1787040000000]],"volumeRatio":1.8594312384959746,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268","defaultTab":"news","newsList":[{"id":"2660454980","title":"港股异动 | 药明合联(02268)午后涨超8% 新加坡基地BCM3双功能产线成功完成GMP放行","url":"https://stock-news.laohu8.com/highlight/detail?id=2660454980","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660454980?lang=zh_cn&edition=full","pubTime":"2026-08-18 13:36","pubTimestamp":1787031383,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药明合联(02268)午后涨超8%，截至发稿，涨7.31%，报69.7港元，成交额5.27亿港元。消息面上，药明合联宣布，位于新加坡基地的生物偶联药抗体中间体和原液双功能生产线BCM3已相继成功完成GMP放行。这一关键进展标志着药明合联全球产能布局迈入新阶段，将有力帮助全球客户加速推进商业化生产，更高效、更灵活地响应多样化的产能需求。作为药明合联全球生产布局的重要拼图，BCM3将与无锡基地的BCM1、BCM2产线高效协同，推动抗体中间体与偶联原液产能实现实质性跃升。根据新加坡基地后续产线建设规划，其制剂生产线DP4亦将于2026年8月底完成GMP放行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK1141","SG9999014674.SGD","BK4588","02268","BK4585","STmain","VXUS","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660569784","title":"医药概念股走强 金斯瑞生物科技（01548）上涨7.67% 机构指板块中长期布局良机已至","url":"https://stock-news.laohu8.com/highlight/detail?id=2660569784","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660569784?lang=zh_cn&edition=full","pubTime":"2026-08-18 10:15","pubTimestamp":1787019309,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药概念股走强，金斯瑞生物科技 上涨7.67%、药明生物上涨4.12%、康龙化成上涨3.87%、药明合联上涨3.85%、凯莱英上涨3.61%、百济神州上涨2.15%。爱建证券表示，2026年初以来医药板块的持续回调与行业基本面、产业趋势发生背离，近期众多上市公司推出现金回购和增持方案，反映出对产业未来发展的充足信心，CXO、创新药及相关产业链已率先发力反弹，医药板块中长期布局良机已至。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988510","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518931.SGD","HK0000306701.USD","BK1191","LU1794554557.SGD","BK1574","LU0979878070.USD","LU2488822045.USD","LU0516422440.USD","LU0456846285.SGD","SG9999014674.SGD","02269","LU0823426480.USD","03759","06160","LU1251922891.USD","02268","LU0051755006.USD","LU0348825331.USD","LU1720050803.USD","LU1770034418.SGD","BK1161","LU2039709279.SGD","LU0039217434.USD","LU0043850808.USD","LU0327786744.USD","LU0516423091.SGD","SG9999002463.SGD","BK1521","LU1880383366.USD","LU1969619763.USD","LU0029874061.USD","09939","BK1588","KURE","BK1583","LU0140636845.USD","LU0348735423.USD","HK0000320223.HKD","BK1589","LU0516422952.EUR","LU2328871848.SGD","LU0326950275.SGD","LU0823426308.USD","LU0307460666.USD","LU0181495838.USD","LU1242518857.USD","159938","LU0708995583.HKD","06821","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125396547","title":"港股创新药概念股盘初活跃，金斯瑞生物科技、海西新药涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125396547","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125396547?lang=zh_cn&edition=full","pubTime":"2026-08-18 09:35","pubTimestamp":1787016939,"startTime":"0","endTime":"0","summary":"8月18日，港股创新药概念股盘初活跃，$金斯瑞生物科技(01548)$、$海西新药(02637)$涨超8%，$药明生物(02269)$、$云顶新耀(01952)$、$百济神州(06160)$、$药明合联(02268)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874061.USD","LU0456846285.SGD","01952","LU0516423174.USD","LU0051755006.USD","LU0359201612.USD","LU0823426308.USD","LU0823426480.USD","LU2488822045.USD","ONC","LU1688375341.USD","BK4588","LU0326950275.SGD","01548","LU1242518857.USD","LU0979878070.USD","02637","LU1720050803.USD","LU0516423091.SGD","BK1610","BK4139","HK0000320223.HKD","02269","LU0327786744.USD","LU0417516902.SGD","LU0588546209.SGD","BK1589","BK4585","HK0000320264.USD","LU0128526141.USD","BK1191","LU0052750758.USD","LU0456827905.SGD","LU0348825331.USD","LU0819121731.USD","LU1880383366.USD","BK1583","SG9999002463.SGD","BK1161","LU0516422440.USD","02268","SG9999002562.SGD","SG9999014674.SGD","LU1242518931.SGD","VXUS","BK1521","BK1576","BK1574","IE00B0JY6N72.USD","LU0140636845.USD","LU0516422952.EUR","HK0000306701.USD","LU2039709279.SGD","LU0043850808.USD","LU3063872942.SGD","LU0417516738.SGD","LU0856984785.SGD","HK0000306685.HKD","LU0572944931.SGD","BK4526","LU0181495838.USD","LU1794554557.SGD","BK1141","KCAI","LU0307460666.USD","LU0039217434.USD","LU0320764599.SGD","KURE","LU0359202008.SGD","LU0516422366.SGD","LU0708995583.HKD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138038637","title":"异动解读｜药明合联盘中上涨3.08%，中报临近叠加板块联动延续走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1138038637","media":"行情直击","labels":[],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138038637?lang=zh_cn&edition=full","pubTime":"2026-08-18 09:35","pubTimestamp":1787016922,"startTime":"0","endTime":"0","summary":"8月18日，药明合联盘中上涨3.08%，报66.95港元/股，成交额2547.42万港元。消息面上，公司此前公告将于8月24日召开董事会审议中期业绩，市场对中报存有积极预期。同属\"药明系\"的药明康德上半年营收同比增长38.93%，归母净利同比增29.43%，管理层全面上调全年业绩指引，持续提振板块情绪。机构面上，Schroders PLC于8月6日增持使好仓比例升至5.01%。当日生命科学工具和服务板块延续强势，金斯瑞生物科技涨7.59%，药明生物涨3.94%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明合联盘中上涨3.08%，中报临近叠加板块联动延续走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173380078","title":"港股创新药概念股盘中走强，和黄医药涨超7%，药明生物、金斯瑞生物科技涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173380078","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173380078?lang=zh_cn&edition=full","pubTime":"2026-08-17 10:08","pubTimestamp":1786932515,"startTime":"0","endTime":"0","summary":"8月17日，港股创新药概念股盘中走强，$和黄医药(00013)$涨超7%，$药明生物(02269)$、$海西新药(02637)$、$金斯瑞生物科技(01548)$涨超5%，$药明康德(02359)$、$药明合联(02268)$涨超4%，$信达生物(01801)$、$石药集团(01093)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1141","LU1226288253.USD","LU0051755006.USD","LU0043850808.USD","LU0516422440.USD","HK0000165453.HKD","LU1794554557.SGD","SG9999002562.SGD","LU0516422952.EUR","LU0516422366.SGD","LU0819121731.USD","IBBQ","IE0008368742.USD","IE00BZ08YR35.GBP","LU1226287792.SGD","HK0000306685.HKD","LU1951186391.HKD","LU0029874061.USD","LU0463099449.HKD","LU0314109678.HKD","LU0348735423.USD","LU0979878070.USD","LU0181495838.USD","BK1610","LU0326950275.SGD","IE00B543WZ88.USD","KURE","LU0348825331.USD","IE00B5MMRT66.SGD","LU1226288170.HKD","BK4007","LU1226287875.USD","LU1993786604.SGD","LU1813983027.USD","01801","LU3063872942.SGD","LU0359202008.SGD","HK0000320264.USD","LU0823426480.USD","LU2097828474.EUR","LU2045819591.USD","VXUS","BK1587","LU0315179316.USD","LU1188198961.HKD","LU0417516902.SGD","LU0140636845.USD","LU0128526141.USD","LU1880383366.USD","LU1242518857.USD","LU2488822045.USD","LNGR","LU0455707207.USD","BK4531","LU0588546209.SGD","LU1720050803.USD","LU1152091754.HKD","LU2125910500.SGD","LU2328871848.SGD","IE00BZ08YS42.EUR","BK1191","LU0456846285.SGD","LU0501845795.SGD","LU0320764599.SGD","BK4585","159992","SG9999014674.SGD","00013","LU1046422090.SGD","BK4588","IE00B031HY20.USD","LU0456827905.SGD","LU0572944931.SGD","LU0823426308.USD","MEDX","IE00B0JY6N72.USD","BK1589","01548","LU2097828631.EUR","LU1688375341.USD","LU0417516738.SGD","HK0000306701.USD","LU0039217434.USD","LU2097828557.USD","01093","BK1161","LU0067412154.USD","LU0856984785.SGD","06978","IE0008369823.USD","HK0000320223.HKD","LU1008478684.HKD","LU0307460666.USD","LU1152091168.USD","LU1960683339.HKD","02637","LU1328277881.USD","LU0359201612.USD","LU0327786744.USD","SG9999002463.SGD","LU0469268626.HKD","LU0348767384.USD","LU0502904849.HKD","KCAI","LU0708995583.HKD","LU2242644610.SGD","BK1521","LU0072913022.USD","LU0244354667.USD","LU2039709279.SGD","BK1515","LU2097828714.EUR","LU0880133367.SGD","BK1588","BK1574","IE00BZ08YT58.USD","LU0516423091.SGD","BK1576","LU0516423174.USD","LU0052750758.USD","LU2097828805.USD","SG9999004220.SGD","LU1969619763.USD","LU1226287529.USD","02359","02269","LU0348766576.USD","LU1242518931.SGD","LU1807302812.USD","HCM","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193642135","title":"异动解读｜药明合联盘中上涨4.11%，中报临近叠加板块联动走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1193642135","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193642135?lang=zh_cn&edition=full","pubTime":"2026-08-17 10:05","pubTimestamp":1786932324,"startTime":"0","endTime":"0","summary":"8月17日，药明合联盘中上涨4.11%，报64.6港元/股，成交额4664.56万港元。消息面上，公司此前公告将于8月24日召开董事会审议中期业绩，市场对中报存在积极预期。同属\"药明系\"的药明康德上半年营收同比增长38.93%，归母净利同比增29.43%，管理层全面上调全年业绩指引，提振板块情绪。机构面上，Schroders PLC于8月6日增持使好仓比例升至5.01%。当日生命科学工具和服务板块整体走强，金斯瑞生物科技涨5.55%，药明生物涨4.16%，药明康德涨3.95%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明合联盘中上涨4.11%，中报临近叠加板块联动走强","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177895527","title":"异动解读｜药明合联盘中下跌3.08%，报61.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177895527","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177895527?lang=zh_cn&edition=full","pubTime":"2026-08-14 13:17","pubTimestamp":1786684665,"startTime":"0","endTime":"0","summary":"8月14日，药明合联盘中下跌3.08%，报61.4港元/股，成交额1.37亿港元。药明合联所在的生命科学工具和服务行业整体走弱，个股中，药明康德跌3.44%，金斯瑞生物科技跌5.62%，药明生物跌1.88%，英矽智能跌5.35%，晶泰控股跌4.7%。药明合联是专注于全球ADC及更广泛生物偶联药物市场的领先CRDMO，主要从事抗体偶联药物及其他生物偶联药物的原料药及药品的研究、发现、开发及生产，主要在国内市场、北美、欧洲和世界其他地区开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659199950","title":"【券商聚焦】中信建投：AI制药大有可为，产业链有望持续受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2659199950","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659199950?lang=zh_cn&edition=full","pubTime":"2026-08-14 08:58","pubTimestamp":1786669118,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，AI制药领域正经历着快速的迭代和变革，算法的更新迭代和算力的支持为AI在制药领域的应用打下了良好的基础。传统药物开发过程花费时间长成本高，且成功率较低，随着已有靶点的新药陆续获批，新药开发难度逐渐上升。近年来AI特别是深度学习的发展，促进了其在包括靶点筛选、分子生成及优化、ADMET预测、晶型预测以及合成路线筛选等的应用，AI用于大分子药物的开发投入也持续增长。AIDD有望重塑早期药物发现的流程，大大加速早期药物筛选的效率及成功率，相关干实验投入的增加以及对湿实验需求持续的增长，有望为下游产业链持续带来增量。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988188","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1719994722.HKD","LU2476274308.USD","LU0417516571.SGD","01530","LU1303224171.USD","LU1770034418.SGD","LU2778985437.USD","09926","601066","02367","06821","AGIX","LU0640798160.USD","QTOC","LU2476274720.SGD","LU0348827113.USD","LU1961090484.USD","BK1197","01477","01789","BK1515","01099","CHAT","SG9999004311.SGD","03933","LU0417516738.SGD","AIPO","02196","LU0634319403.HKD","LU0348735423.USD","BK1585","LU0828237510.HKD","LU0348784397.USD","09688","02228","KCE","LU2328871848.SGD","BK1191","VTHR","LU0348766576.USD","06160","ARTY","KURE","BK1500","IE00B5MMRT66.SGD","LU0348783233.USD","LU0348825331.USD","LU0540923850.HKD","LU0561508036.HKD","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658369969","title":"创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2658369969","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658369969?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:15","pubTimestamp":1786418137,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念持续走强，截至发稿，金斯瑞生物科技 涨6.87%，再鼎医药涨5.51%，同源康医药-B涨4.81%，晶泰控股涨3.94%，药明合联涨3.92%，翰森制药涨3.76%，亚盛医药涨3.63%，百济神州涨3.38%，药明康德涨3.03%，诺诚健华涨2.83%，石药集团涨2.78%。国元国际证券亦表示，出海交易量价齐升，中国创新药全球地位持续提升。中国创新药出海持续超预期，上半年997亿美元的交易总额和全球TOP10中独占8席的成绩，充分验证了中国创新药资产的全球竞争力。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987912","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","LU2039709279.SGD","LU1813983027.USD","LNGR","LU1226288170.HKD","BK1588","KURE","03692","LU1303224171.USD","02268","MEDX","02228","06855","LU1993786604.SGD","LU0880133367.SGD","IE00B031HY20.USD","BK1515","LU2328871848.SGD","02410","IE00B5MMRT66.SGD","LU2488822045.USD","HK0000306685.HKD","LU2242644610.SGD","LU0326950275.SGD","06160","HK0000320223.HKD","IBBQ","LU1226287875.USD","BK1583","IE00BZ08YS42.EUR","BK1576","BK1500","LU1226287792.SGD","LU1951186391.HKD","01548","IE00B543WZ88.USD","01093","06978","LU1152091168.USD","LU2125910500.SGD","159992","02359","LU0072913022.USD","LU0315179316.USD","IE00BZ08YT58.USD","09969","BK1161","09688","IE00BZ08YR35.GBP","BK1617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127067370","title":"异动解读｜药明合联盘中上涨3.6%，机构增持突破举牌线叠加中报预期升温","url":"https://stock-news.laohu8.com/highlight/detail?id=1127067370","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127067370?lang=zh_cn&edition=full","pubTime":"2026-08-11 10:07","pubTimestamp":1786414037,"startTime":"0","endTime":"0","summary":"8月11日，药明合联盘中上涨3.6%，报64.8港元，成交额8781.99万港元。消息面上，Schroders PLC于8月6日增持药明合联约10.90万股，持股比例由4.99%升至5.01%，触发举牌披露线。同时，公司将于8月24日召开董事会审议中期业绩，市场对ADC外包龙头高增长预期持续升温。板块联动延续，同日药明生物涨3.25%、金斯瑞生物科技涨7.37%，资金提前布局意愿明显。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192078741","title":"药明合联：Schroders PLC增持，好仓比例升至5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192078741","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192078741?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:13","pubTimestamp":1786353207,"startTime":"0","endTime":"0","summary":"Schroders PLC于2026年8月6日以每股均价55.3979港元买入药明合联股份10.90万股，涉资约603.84万港元。Schroders PLC此次增持前持有药明合联好仓6330.90万股，占比4.99%；增持后持股量为6341.80万股，好仓比例升至5.01%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123325853","title":"异动解读｜药明合联盘中上涨3.39%，中报业绩预期升温叠加CXO板块联动走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1123325853","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123325853?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:34","pubTimestamp":1786325648,"startTime":"0","endTime":"0","summary":"8月10日，药明合联盘中上涨3.39%，报63.65港元，成交额6039.84万港元。消息面上，公司将于8月24日召开董事会审议中期业绩，市场对ADC外包龙头高增长预期持续升温。此前里昂上调公司目标价至82.6港元，维持\"跑赢大市\"评级，预测收入及经调整纯利增长超越指引；大和首予\"买入\"评级，目标价78港元，列为中国CXO行业首选股。板块联动效应延续，同日药明康德涨4.63%、药明生物涨3.58%、英矽智能涨7.31%，全球生物科技融资回暖及ADC研发投资强劲，资金提前布局意愿明显。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657693089","title":"港股异动 | 创新药概念多数走高 创新药企陆续迎业绩窗口 后续学术会议有望带来密集催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2657693089","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657693089?lang=zh_cn&edition=full","pubTime":"2026-08-07 11:24","pubTimestamp":1786073069,"startTime":"0","endTime":"0","summary":"消息面上，近期多家创新药企业陆续发布业绩相关公告。从百济神州净利润同比增超6倍，到药明康德大幅上调全年收入指引，再到信达生物、荣昌生物各自兑现增长逻辑，创新药产业链正迎来\"业绩落地+催化密集\"的共振窗口。值得一提的是，海外顶级医学会议临床数据披露有望成为短期核心催化。其次，该行长期看好国产创新药发展趋势，行业景气度向上，出海持续演绎，后续学术会议陆续召开，临床数据有望读出，带来密集催化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","02268","LU0823426308.USD","LU1794554557.SGD","BK1588","LU1242518931.SGD","02269","06978","LU0359202008.SGD","LU0708995583.HKD","LU0307460666.USD","LU0181495838.USD","LU0348825331.USD","KURE","01672","LNGR","LU0348735423.USD","09688","159992","LU0979878070.USD","LU2039709279.SGD","LU0856984785.SGD","BK1515","LU0051755006.USD","07666","KCAI","LU0043850808.USD","LU2488822045.USD","LU0417516738.SGD","SG9999002463.SGD","LU0516422366.SGD","BK1589","MEDX","BK1574","LU0039217434.USD","LU0819121731.USD","BK1161","BK1521","LU0572944931.SGD","LU0456846285.SGD","LU0326950275.SGD","LU0327786744.USD","SG9999002562.SGD","LU0823426480.USD","LU0359201612.USD","LU1720050803.USD","VXUS","LU0417516902.SGD","LU1880383366.USD","LU3063872942.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657660793","title":"医药股强势走强 再鼎医药（09688）涨13.97%、药明生物（02269）涨5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657660793","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657660793?lang=zh_cn&edition=full","pubTime":"2026-08-07 10:06","pubTimestamp":1786068387,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股强势走强，再鼎医药 涨13.97%，药明生物涨5.41%，药明合联涨4.78%，药明康德涨4.73%，百济神州涨3.66%，荣昌生物涨2.33%，泰格医药涨2.07%。。国信证券表示，2026年版国家基本药物目录近期正式发布，这是目录时隔8年再次进行系统调整。新版目录结合疾病谱变化和临床用药需求，进一步补充慢性病、儿童、专科疾病及中医药优势病种用药，并对剂型、规格进行优化，提升药品在不同人群和医疗场景中的适用性。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987694","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348767384.USD","SG9999002562.SGD","BK4531","LU1770034418.SGD","BK1515","LU0140636845.USD","LU2039709279.SGD","LU0181495838.USD","KURE","06160","LU0348735423.USD","LU0516422440.USD","LU0348766576.USD","BK4526","LU0516423174.USD","LU0572944931.SGD","BK1574","LU2488822045.USD","09688","IE00B0JY6N72.USD","LU0516422952.EUR","LU1794554557.SGD","09939","02359","LU0588546209.SGD","LU1880383366.USD","LU0039217434.USD","LU0823426308.USD","LU2045819591.USD","ZLAB","LU0052750758.USD","LU0051755006.USD","BK4585","LU0359202008.SGD","02268","LU0456846285.SGD","LU1303224171.USD","LU1720050803.USD","BK1589","LU0043850808.USD","159938","LU0326950275.SGD","BK1583","LU0856984785.SGD","03347","09995","02269","LU2328871848.SGD","LU0327786744.USD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131943054","title":"异动解读｜药明合联盘中上涨3.07%，中报业绩预期升温叠加CXO板块持续走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1131943054","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131943054?lang=zh_cn&edition=full","pubTime":"2026-08-07 09:47","pubTimestamp":1786067235,"startTime":"0","endTime":"0","summary":"8月7日，药明合联盘中上涨3.07%，报57.1港元，成交额3545.6万港元。消息面上，公司将于8月24日召开董事会审议中期业绩，市场对ADC外包龙头高增长预期持续升温。此前里昂上调公司目标价至82.6港元，维持\"跑赢大市\"评级，预测收入及经调整纯利增长超越指引；大和首予\"买入\"评级，目标价78港元，列为中国CXO行业首选股。同日板块联动效应延续，康龙化成涨5.87%、药明生物涨3.43%、药明康德涨3.56%，全球生物科技融资回暖及ADC研发投资强劲，资金提前布局意愿明显。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明合联盘中上涨3.07%，中报业绩预期升温叠加CXO板块持续走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195362030","title":"异动解读｜药明合联盘中上涨4.34%，中报业绩预期升温叠加多家大行看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1195362030","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195362030?lang=zh_cn&edition=full","pubTime":"2026-08-06 09:51","pubTimestamp":1785981081,"startTime":"0","endTime":"0","summary":"8月6日，药明合联盘中上涨4.34%，报56.5港元，成交额6446.78万港元。消息面上，公司将于8月24日召开董事会审议中期业绩，市场对ADC外包龙头高增长预期持续升温。此前里昂上调公司目标价至82.6港元，维持\"跑赢大市\"评级，预测收入及经调整纯利增长超越指引；大和首予\"买入\"评级，目标价78港元，列为中国CXO行业首选股。同行业板块延续强势，同日金斯瑞生物科技涨5.07%、药明生物涨2.66%，板块联动效应显著。全球生物科技融资回暖及ADC研发投资强劲，资金提前布局意愿明显。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明合联盘中上涨4.34%，中报业绩预期升温叠加多家大行看好","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143458829","title":"药明合联7月股份变动月报表，已发行股份增至1,266,466,942股","url":"https://stock-news.laohu8.com/highlight/detail?id=1143458829","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143458829?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:46","pubTimestamp":1785919599,"startTime":"0","endTime":"0","summary":"根据WuXi XDC Cayman Inc.药明合联生物技术有限公司于2026年8月5日发布的截至2026年7月31日的月报表显示，公司法定股本维持在10,000,000,000股，面值每股0.00005美元，法定股本总额500,000美元，与上月相比并无变动。在股权激励和期权方面，药明合联多项首次公开发售前购股权计划于当月合计行使4,904,388份购股权，相关行使共带来人民币18,722,703.86元资金。截至本月末，药明合联已发行股份数为1,266,466,942股，股本总额较上月保持小幅增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103207641","title":"异动解读｜药明合联盘中上涨5.66%，CXO板块集体走强叠加中报业绩预期升温","url":"https://stock-news.laohu8.com/highlight/detail?id=1103207641","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103207641?lang=zh_cn&edition=full","pubTime":"2026-08-04 09:33","pubTimestamp":1785807185,"startTime":"0","endTime":"0","summary":"8月4日，药明合联盘中上涨5.66%，报54.5港元，成交额5321.09万港元。消息面上，CXO板块当日集体走强，同行业药明康德涨12.28%、康龙化成涨6.78%，板块联动效应显著。公司将于8月24日披露中期业绩，市场对ADC外包龙头高增长预期持续升温，叠加全球生物科技融资回暖及ADC研发投资强劲，资金提前布局意愿明显。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129630386","title":"异动解读｜药明合联盘中下跌3.21%，野村下调目标价并削减盈利预测","url":"https://stock-news.laohu8.com/highlight/detail?id=1129630386","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129630386?lang=zh_cn&edition=full","pubTime":"2026-07-30 10:20","pubTimestamp":1785378001,"startTime":"0","endTime":"0","summary":"7月30日，药明合联盘中下跌3.21%，报51.3港元/股，成交额6272.08万港元。消息面上，野村于7月29日发表研报，将药明合联目标价由87.73港元下调至82.6港元，维持\"买入\"评级，同时因汇率负面影响及东曜药业收购相关并购费用，将公司2026财年盈利预测下调22.3%。野村预期公司上半年经营利润率因东曜药业收购带来的较高管理费用下降至27.4%，同比跌1.1个百分点，叠加较高汇兑损失，预期上半年股东应占净利润为7.47亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明合联盘中下跌3.21%，野村下调目标价并削减盈利预测","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197790677","title":"异动解读｜药明合联盘中下跌3.04%，报52.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197790677","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197790677?lang=zh_cn&edition=full","pubTime":"2026-07-28 11:12","pubTimestamp":1785208372,"startTime":"0","endTime":"0","summary":"7月28日，药明合联盘中下跌3.04%，报52.7港元/股，成交额6988.24万港元。药明合联所在的生命科学工具和服务行业中，板块整体承压，个股中，金斯瑞生物科技跌0.59%，药明康德跌0.32%，英矽智能跌7.79%，药明生物跌0.93%，晶泰控股跌4.18%。药明合联是一家主要从事抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司，主要在国内市场、北美、欧洲和世界其他地区市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":0.0872},{"period":"1month","weight":0.3105},{"period":"3month","weight":0.2106},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1348},{"period":"ytd","weight":0.1498}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":0.037},{"period":"3month","weight":-0.007},{"period":"6month","weight":-0.0462},{"period":"1year","weight":0.0117},{"period":"ytd","weight":-0.0062}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明合联生物技术有限公司是一家主要从事提供提供抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司。该公司的服务包括生物偶联药物、单克隆抗体中间体及生物偶联药物相关连接子及有效载荷的发现、工艺开发及优良生产质量管理规范（GMP）生产。该公司透过按有偿服务（FFS）基准的合约和按全时当量（FTE）基准的合约向客户提供CRDMO服务。该公司主要在国内市场、北美、欧洲和世界其他地区市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}